Margoles L, Rio C, Franco-Paredes C

Idioma: Ingles.
Referencias bibliográficas: 24
Paginas: 110-116
Archivo PDF: 275.16 Kb.

FRAGMENTO

Sin resumen

REFERENCIAS (EN ESTE ARTÍCULO)

1. Walker SL, Lockwood DNJ. The clinical and immunological features of leprosy. Br Med Bull 2006;77-78:103-121.

2. World Health Organization. Global strategy for further reducing the leprosy burden and sustaining leprosy control activities 2006-2010. Operational Guidelines. Geneva: World Health Organization; 2006. Contract No.: WHO/CDS/CPE/CEE/2005.53.

3. World Health Organization. Leprosy (Hansen disease). Report by Secretariat. Executive Board, December 16, 2010. Geneva.

4. Rodriguez O. La lucha contra la lepra en México. Rev Fac Med UNAM 2003;46:109-113.

5. Scollard DM. The biology of nerve injury in leprosy. Lepr Rev 2008;79:242-253.

6. Yoder LJ. Management of reactions in Hansen’s Disease. The Star. Carville (Louisiana): Gillis W. Long Hansen’s Disease Program; 1996.

7. World Health Organization. Global leprosy situation, beginning of 2008. Wkly Epidemiol Rec 2008;83:293-300.

8. Panamerican Health Organization. Situation report: leprosy in the Americas, 2007. Available at: http://www.paho.org/English/AD/DPC/CD/lep-sit-reg-2007.pdf

9. Anderson H, Stryjewska B, Boyanton BL, Schwartz MR. Hansen disease in the United States in the 21st century: a review of the literature. Arch Pathol Lab Med 2007;131:982-986.

10. Ooi WW, Moschella SL. Update on leprosy in immigrants in the United States: status in the year 2000. Clin Infect Dis 2001;32:930-937.

11. Franco-Paredes C, Jacob JT, Stryjewska B, Yoder L. Two patients with leprosy and the sudden appearance of inflammation in the skin and new sensory loss. PLoS Negl Trop Dis 2009;3:e425.

12. Britton WJ, Lockwood DNJ. Leprosy. Lancet 2004;363:1209-1219.

13. Ridley DS, Jopling WH. Classification of leprosy according to immunity. A five-group system. Int J Lepr Other Mycobac Dis1966;34:255-273.

14. Scollard DM, Adams LB, Gillis TP, Krahenbuhl JL, Truman RW, Williams DL. The continuing challenges of leprosy. Clin Microbiol Rev 2006;19:338-381.

15. Boggild AK, Keystone JS, Kain KC. Leprosy: a primer for Canadian physicians. CMAJ 2004;170:71-78.

16. van Brakel WH, Nicholls PG, Das L, Barkataki P, Suneetha SK, Jadhav RS, et al. The INFIR Cohort Study: investigating prediction, detection, and pathogenesis of neuropathy and reactions in leprosy. Methods and baseline results of a cohort of multibacillary leprosy patients in North India. Lepr Rev 2005;76:14-34.

17. van Brakel WH, Nicholls PG, Wilder-Smith EP, Das L, Barkataki P, Lockwood DNJ, et al. Early diagnosis of neuropathy in leprosy comparing diagnostic tests in a large prospective study (the INFIR Cohort Study). PLoS Negl Trop Dis 2008;2:e212.

18. Haslett PA, Roche P, Butlin CR, Macdonald M, Shrestha N, Manandhar R, et al. Effective treatment of erythema nodosum leprosum with thalidomide is associated with immune stimulation. J Infect Dis 2005;192:2045-2053.

19. Graham A, Furlong S, Margoles L, Owusu K, Franco-Paredes C. Clinical management of leprosy reactions. Infect Dis Clin Pract 2010;18:235-238.

20. Lockwood DNJ, Lucas SB, Desikan KV, Ebenezer G, Suneetha S, Nicholls P. The histological diagnosis of leprosy type 1 reactions: identification of key variables and an analysis of the process of histological diagnosis. J Clin Pathol 2008;61:595-600.

21. Deps PD, Lockwood DNJ. Leprosy occurring as immune reconstitution syndrome. Trans R Soc Trop Med Hyg 2008;102:966-968.

22. Kahawita IP, Lockwood DNJ. Towards understanding the pathology of erythema nodosum leprosum. Trans R Soc Trop Med Hyg 2008;102:329-337.

23. Walker SL, Waters MF, Lockwood DNJ. The role of thalidomide in the management of erythema nodosum leprosum. Lepr Rev 2007;78:197-215.

24. Pocaterra L, Jain S, Reddy R, Muzaffarullah S, Torres O, Suneetha S, et al. Clinical course of erythema nodosum leprosum: an 11-year cohort study in Hyderabad, India. Am J Trop Med Hyg 2006;74:868-879.